Denali Therapeutics Secures $275 Million Royalty Deal With Royalty Pharma
Denali Therapeutics Inc. has partnered with Royalty Pharma plc in a $275 million synthetic royalty funding agreement for tividenofusp alfa, an investigational therapy for Hunter syndrome. Royalty Pharma will pay $200 million upon FDA approval and $75 million upon European approval by 2029. In return, they will receive a 9.25% royalty on worldwide net sales until a specified return multiple is reached.
Denali Therapeutics Inc. has entered into a partnership with Royalty Pharma plc through a $275 million synthetic royalty funding agreement based on future net sales of tividenofusp alfa, Denali’s lead investigational therapy for Hunter syndrome. Under the terms, Royalty Pharma will make an initial payment of $200 million upon FDA accelerated approval of tividenofusp alfa, with an additional $75 million payment contingent on European Medicines Agency approval by the end of 2029. In return, Royalty Pharma will receive a 9.25% royalty on worldwide net sales of tividenofusp alfa, with royalty payments ending once a specified return multiple is reached. The agreement aims to support the development and potential launch of this innovative therapy. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Denali Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001714899-25-000208), on December 04, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT) Original Document: here
